Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

NCT05901285 is registered in ClinicalTrials.gov with Vaxiion Therapeutics as lead sponsor.

NCT NCT05901285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05901285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Lead sponsor
Vaxiion Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
November 2, 2023
Completion date
November 30, 2027
Enrollment
48 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, advanced solid tumors appropriate for treatment with either nivolumab or pembrolizumab